Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
Department of Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Front Immunol. 2022 Oct 11;13:1016059. doi: 10.3389/fimmu.2022.1016059. eCollection 2022.
The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.
免疫治疗方法在血液系统癌症中的成功部分受到免疫抑制微环境的影响。髓源性抑制细胞（MDSC）是这种抑制环境的关键组成部分，并且经常与肿瘤细胞的存活和耐药性相关。根据其形态和表型，MDSC 通常分为多形核髓系抑制细胞（PMN-MDSC 或 G-MDSC）和单核细胞 MDSC（M-MDSC），两者均具有免疫抑制功能。MDSC 在血液系统癌症中的表型、功能和预后价值已得到深入研究；然而，针对该细胞群体的治疗靶向仍然具有挑战性，需要进一步研究。在这篇综述中，我们将总结 MDSC 的预后价值以及靶向 MDSC（或 MDSC 亚型）在血液系统癌症中的不同尝试。我们将讨论使用 MDSC 靶向方法的益处、挑战和机遇，旨在增强目前使用的细胞和非细胞免疫疗法的抗肿瘤免疫反应。
